Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.
Khandelwal P, Teusink-Cross A, Davies SM, Nelson AS, Dandoy CE, El-Bietar J, Marsh RA, Kumar AR, Grimley MS, Jodele S, Myers KC. Khandelwal P, et al. Biol Blood Marrow Transplant. 2017 Jul;23(7):1122-1127. doi: 10.1016/j.bbmt.2017.03.029. Epub 2017 Mar 23. Biol Blood Marrow Transplant. 2017. PMID: 28344057 Free article.
Bortezomib for refractory autoimmunity in pediatrics.
Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AH. Khandelwal P, et al. Biol Blood Marrow Transplant. 2014 Oct;20(10):1654-9. doi: 10.1016/j.bbmt.2014.06.032. Epub 2014 Jun 28. Biol Blood Marrow Transplant. 2014. PMID: 24979732 Free article. Clinical Trial.
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM. Marsh RA, et al. Among authors: khandelwal p. Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10. Biol Blood Marrow Transplant. 2015. PMID: 25865646 Free PMC article.
A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.
Khandelwal P, Fukuda T, Mizuno K, Teusink-Cross A, Mehta PA, Marsh RA, Kashuba ADM, Vinks AA, Davies SM. Khandelwal P, et al. Biol Blood Marrow Transplant. 2016 Oct;22(10):1829-1835. doi: 10.1016/j.bbmt.2016.08.001. Epub 2016 Aug 3. Biol Blood Marrow Transplant. 2016. PMID: 27498124 Free article.
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.
Khandelwal P, Bleesing JJ, Davies SM, Marsh RA. Khandelwal P, et al. Biol Blood Marrow Transplant. 2016 Nov;22(11):2011-2018. doi: 10.1016/j.bbmt.2016.08.013. Epub 2016 Aug 16. Biol Blood Marrow Transplant. 2016. PMID: 27543157 Free article.
439 results